<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785186</url>
  </required_header>
  <id_info>
    <org_study_id>PanACEA-MAMS-TB-01</org_study_id>
    <nct_id>NCT01785186</nct_id>
  </id_info>
  <brief_title>Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</brief_title>
  <official_title>A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Hoelscher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sequella, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multiple-arm, multiple-stage (MAMS), phase 2, open label, randomized,
      controlled clinical trial that will compare the efficacy and safety of four experimental four
      drug regimens with a standard control regimen in patients with smear positive, pulmonary
      tuberculosis (TB). Patients will be randomly allocated to the control or one of the four
      experimental regimens in the ratio 2:1:1:1:1. Experimental regimens will be given for 12
      weeks. Thereafter, participants in the experimental arms will receive continuation phase
      treatment for 14 weeks containing standard-dose rifampicin and isoniazid. All participants
      will receive 25 mg of vitamin B6 (pyridoxine) with every dose of INH to prevent INH‐related
      neuropathy. Interim analyses will be conducted during the trial for efficacy, with the aim of
      identifying experimental arms that perform below a pre‐specified efficacy threshold; these
      arms will then be stopped from further recruitment.

      Following the first scheduled interim analysis on March 3rd, the Trial Steering Committee
      (TSC) followed a recommendation of the independent data monitoring committee (IDMC) and has
      stopped the enrolment into two of the arms in the MAMS-TB trial: HRZQ and HR20ZQ, based on
      these arms not meeting the pre-specified gain in efficacy over control. Importantly, there
      was no safety concern that prompted stopping recruitment to these arms. They recommended that
      recruitment to arm 2 (HRZQ) and 3 (HR20ZQ) be terminated as there was insufficient evidence
      that these regimens could shorten treatment. Importantly, there was no evidence that either
      arm was inferior to standard treatment (the control arm) with regards to efficacy. There was,
      however, sufficient evidence that the other intervention arms HR35ZE and HR20ZM could shorten
      treatment to continue enrolling patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II, multi‐arm, multi‐stage, open label, prospectively randomized, controlled
      clinical trial will compare the efficacy and safety of four experimental regimens with the
      control, standard treatment regimen in patients with smear positive, pulmonary tuberculosis
      (TB). There will be four experimental regimens. Participants will be randomly allocated to
      control or one of the four experimental intensive phase regimens in the ratio 2:1:1:1:1. The
      control and 4 experimental regimens are:

      Control: HRZE isoniazid, rifampicin standard, pyrazinamide, ethambutol Arm 1: HRZQlow
      isoniazid, rifampicin standard, pyrazinamide, SQ109 150 mg Arm 2: HRZQhigh isoniazid,
      rifampicin standard, pyrazinamide, SQ109 300 mg Arm 3: HR20ZQhigh isoniazid, rifampicin 20
      mg/kg, pyrazinamide, SQ109 300 mg Arm 4: HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide,
      moxifloxacin 400mg

      Up to 372 participants will be randomized into this study, with 124 participants being
      randomized to the control arm and 62 participants to each experimental arm. With an expected
      loss to follow‐up of 5%, the final power of the study to detect a hazard ratio of 1.8 for
      culture conversion to negative will be 90%, at the 5% significance level.

      Participants will be randomised using a probabilistic minimisation algorithm based on site,
      baseline bacterial load as measured by GeneXpert MTB/RIF®, and HIV status. The allocated
      intensive phase of the four experimental arms will be administered daily for twelve weeks.
      During this time, participants will visit the study clinic on a weekly basis for sputum
      collection, safety monitoring and receipt of study medication. After the completion of the
      experimental treatment, participants in the experimental arms will receive daily standard
      continuation phase treatment for 14 weeks containing standard‐dose RIF and INH to complete
      their TB treatment course. Participants in the control arm will receive eight weeks of
      intensive four‐drug treatment (HRZE, followed by 18 weeks of the HR continuation phase
      treatment in line with the current WHO recommendations.

      All participants will receive 25mg of Vitamin B6 (pyridoxine) with every dose of treatment in
      order to prevent INH‐related neuropathy.

      Interim analyses will be conducted during the trial for efficacy at predetermined times, with
      the aim of identifying experimental arms that perform below a pre‐specified efficacy
      threshold. There will be no further recruitment to these arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycobacteriology Identification and Characterization by PCR and MIC</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Cultures grown from the screening period, and the last sputum sample with mycobacteriological growth will be assessed as follows:
Identification of M. tuberculosis complex and RIF resistance by PCR (GeneXpert MTB/RIF®),
First-line drug susceptibility testing of the M. tuberculosis isolates using the MGIT system for sensitivity to rifampicin; isoniazid, pyrazinamide, moxifloxacin or ethambutol.
Minimum inhibitory concentrations (MIC) of SQ109, rifampicin and moxifloxacin.
Typing of the infecting strain(s) by molecular methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Including AUC, Cl, t1/2, Vd, and Protein Binding</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:
area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0‐24) (in h*ng/mL)
the observed maximum concentration (Cmax( (in ng/mL)
time to reach Cmax (Tmax)(in hours)
the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),
clearance (Cl) (in mL/minute),
volume of distribution (Vd) (in L),
elimination half‐life (T1/2,) (in hours)
free (protein‐unbound) fraction (for rifampicin only) (in percent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Including AUC0‐24/MIC (h*ng/mL) and Cmax/MIC (ng/mL)</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>By combining pharmacokinetic parameters and MIC values (see below), the pharmacodynamic indices AUC0‐24/MIC (h*ng/mL) and Cmax/MIC (ng/mL) will be calculated for individual patients for experimental drugs administered. Pharmacokinetic parameters and pharmacodynamic indices will be related to efficacy and safety/tolerability endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Negative Culture on Liquid and Solid Media</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Time to a convert to a single negative culture on liquid and solid media</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Negative Sputum Cultures</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Proportion of patients converting to negative sputum culture (2 consecutive weekly cultures) in liquid and solid media</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Time to Positivity</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Rate of change in time to positivity in BD MGIT 960® liquid culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Quantitative PCR During Therapy</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>GeneXpert MTB/RIF (Xpert) quantitative PCR results (counts per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Treatment Failure (Relapse or Emergence of Drug-resistance)</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Frequency of treatment failures (number of patients with relapse and/or development of drug resistance) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Baseline Laboratory Safety Parameters During Treatment and Follow-up</measure>
    <time_frame>0 - 12 weeks</time_frame>
    <description>Frequency tables will be generated for visual acuity tests, 12 lead ECGs, clinical chemistry metrics, haematology, and urinalysis</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1 (R35)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRZQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HR20ZQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HR20ZM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SQ109</intervention_name>
    <description>SQ109 300 mg</description>
    <arm_group_label>HRZQ</arm_group_label>
    <arm_group_label>HR20ZQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin 10 to 35 mg/kg</description>
    <arm_group_label>Arm 1 (R35)</arm_group_label>
    <arm_group_label>HRZQ</arm_group_label>
    <arm_group_label>HR20ZQ</arm_group_label>
    <arm_group_label>HR20ZM</arm_group_label>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin 400mg</description>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazid</intervention_name>
    <description>isoniazid 75 mg</description>
    <arm_group_label>Arm 1 (R35)</arm_group_label>
    <arm_group_label>HRZQ</arm_group_label>
    <arm_group_label>HR20ZQ</arm_group_label>
    <arm_group_label>HR20ZM</arm_group_label>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyrazinamide</intervention_name>
    <description>pyrazinamide 400 mg</description>
    <arm_group_label>Arm 1 (R35)</arm_group_label>
    <arm_group_label>HRZQ</arm_group_label>
    <arm_group_label>HR20ZQ</arm_group_label>
    <arm_group_label>HR20ZM</arm_group_label>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethambutol</intervention_name>
    <description>ethambutol 275 mg</description>
    <arm_group_label>Arm 1 (R35)</arm_group_label>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>pyridoxine</intervention_name>
    <description>pyridoxine 25 mg</description>
    <arm_group_label>Arm 1 (R35)</arm_group_label>
    <arm_group_label>HRZQ</arm_group_label>
    <arm_group_label>HR20ZQ</arm_group_label>
    <arm_group_label>HR20ZM</arm_group_label>
    <arm_group_label>HRZE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. The patient has given free, signed written or witnessed oral informed consent for
             study participation prior to all trial‐related procedures, including HIV testing if
             HIV serostatus is not known or the last documented negative is more than four weeks
             ago.

          2. The patient has a diagnosis of pulmonary tuberculosis from a health clinic established
             by sputum smear and/or GeneXpert MTB/RIF® and/or chest X‐ray.

          3. An adequate sputum bacterial load is confirmed by a Ziehl‐Neelsen stained smear in the
             study laboratory, done from concentrated sputum found at least 1+ on the IUATLD/WHO
             scale.

          4. The patient has a valid rapid test result (GeneXpert MTB/RIF®) from the sputum
             positive for MTB complex, and indicating susceptibility to Rifampicin. This test must
             be done in the study laboratory.

          5. The patient is aged at least 18 years at the day of informed consent.

          6. The patient has a body weight in light clothing and without shoes of at least 35 kg,
             but not more than 90 kg.

          7. Female patients of childbearing potential must have a negative serum pregnancy test,
             and consent to practise an effective method of birth control until week 26. Effective
             birth control for female patients has to include two methods, including methods that
             the patient's sexual partner(s) use. At least one must be a barrier method. Female
             patients are considered not to be of childbearing potential if they are
             post‐menopausal with no menses for the last 12 months, or surgically sterile (this
             condition is fulfilled by bilateral oophorectomy, hysterectomy, and by tubal ligation
             which is done at least 12 months prior to enrolment).

          8. Male patients must consent to use an effective contraceptive method, if their sexual
             partner(s) is/are of childbearing potential, and if they are not surgically sterile
             (see 6.). Contraception by male participants must be practised until at least week 24
             to cover the period of spermatogenesis. Contraceptive methods used by male
             participants may include hormonal methods used by the partner(s).

          9. The patient has a firm home address that is readily accessible for visiting and
             willingness to inform the study team of any change of address during trial
             participation, or will be compliant to study schedule, in the discretion of the
             investigator.

        Exclusion Criteria

          1. Circumstances that raise doubt about free, uncoerced consent to study participation
             (e.g. in a prisoner or mentally handicapped person)

          2. Poor General Condition where delay in treatment cannot be tolerated or death within
             three months is likely.

          3. The patient is pregnant or breast‐feeding.

          4. The patient has an HIV infection and is receiving antiretroviral treatment (ART),
             and/or is likely to require ART during the twelve weeks of experimental study
             treatment as per local guidelines.

          5. The patient has a known intolerance to any of the study drugs, or concomitant
             disorders or conditions for which SQ109, rifampicin, moxifloxacin, or standard TB
             treatment are contraindicated.

          6. The patient has an history or evidence of clinically relevant metabolic,
             gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or any
             other condition that will influence treatment response, study adherence or survival in
             the judgement of the investigator, especially:

             clinically significant evidence of severe TB (e.g. miliary TB, TB meningitis. Limited
             lymph node involvement will not lead to exclusion); serious lung conditions other than
             TB or severe respiratory impairment in the discretion of the investigator; neuropathy,
             epilepsy or significant psychiatric disorder; uncontrolled and/or insulin‐dependent
             diabetes; cardiovascular disease such as myocardial infarction, heart failure,
             coronary heart disease, uncontrolled hypertension (systolic blood pressure ≥160 mmHg
             and/or diastolic blood pressure of ≥100 mmHg on two occasions), arrhythmia, or
             tachyarrhythmia; long QT syndrome (see criterion 9.), or family history of long QT
             syndrome or sudden death of unknown or cardiac‐related cause; Plasmodium spp.
             parasitemia as indicated by thick blood smear or a positive rapid test present at
             screening; Alcohol or other drug abuse that is sufficient to significantly compromise
             the safety or cooperation of the patient, includes substances prohibited by the
             protocol, or has led to significant organ damage at the discretion of the
             investigator.

          7. History of previous TB within the last five years.

          8. Laboratory: at screening one or more of the following abnormalities were observed for
             the patient in screening laboratory: Serum amino aspartate transferase (AST) and/or
             serum alanine aminotransferase (ALT) activity &gt;3x the upper limit of normal; Serum
             total bilirubin level &gt;2.5 times the upper limit of normal; Creatinine clearance
             (CrCl) level lower than 30 mls/min; Complete blood count with hemoglobin level &lt;7.0
             g/dL; Platelet count &lt;50,000/mm3; Serum potassium below the lower level of normal;

          9. ECG findings in the screening ECG: QTcB and/or QTcF of &gt;0.450 s; atrioventricular (AV)
             block with PR interval &gt; 0.20 s; prolongation of the QRS complex over 120
             milliseconds; other changes in the ECG that are clinically relevant as per discretion
             of the investigator.

         10. The patient has had treatment with any other investigational drug within 1 month prior
             to enrolment, or enrolment into other clinical (intervention) trials is planned during
             week 1‐26

         11. Previous anti‐TB treatment: the patient has had previous treatment with drugs active
             against M. tuberculosis within the last 3 months, including but not limited to INH,
             EMB, RIF, PZA, amikacin, cycloserine, rifabutin, streptomycin, kanamycin,
             para‐aminosalicylic acid, rifapentine, thioacetazone, capreomycin, fluoroquinolones,
             thioamides.

         12. QT prolonging medications: Administration within 30 days prior to study start,
             anticipated administration during the study period, or during the 12 weeks of
             experimental treatment, of any QT‐prolonging agents such as, but not limited to,
             azithromycin, bepridil chloroquine, chlorpromazine, cisapride, cisapride,
             clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin,
             halofantrine, haloperidol, ibutilide, levomethadyl, lumefantrine, mefloquine,
             mesoridazine, methadone, moxifloxacin, pentamidine, pimozide, procainamide, quinidine,
             quinine, roxithromycin, sotalol, sparfloxacin, terfenadine, thioridazine. Exceptions
             may be made for participants who have received 3 days or less of one of these drugs or
             substances, if there has been a wash‐out period equivalent to at least 5 half‐lives of
             that drug or substance.

             Patients who have ever received amiodarone will be excluded from study participation.

         13. CYP 450 inducers/inhibitors: administration within 30 days prior to dosing, or planned
             administration until the end of week 12, of any drug(s) or substance(s) known to be
             strong inhibitors or inducers of cytochrome P450 enzymes, or specific
             inhibitors/inducers of SQ109‐metabolizing enzymes as Exceptions may be made for
             subjects that have received 3 days or less of one of these drugs or substances, if a
             wash‐out period equivalent to at least 5 half‐lives of that drug or substance prior to
             study treatment is granted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hoelscher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum of the University of Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Boeree, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TASK Applied Science</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town, Centre for Tuberculosis Research Innovation</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Health Consortium</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute for Health Research</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifakara Health Institute</name>
      <address>
        <city>Bagamoyo</city>
        <zip>P.O.Box 74</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMR - Mbeya Medical Research Programme</name>
      <address>
        <city>Mbeya</city>
        <zip>P.O. Box 2410</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical Centre (KCMC) / Kilimanjaro Clinical Research Institute (KCRI) (with affiliated field sites such as Kibong'oto National Tuberculosis Hospital Same, Mererani, Chekereni and Mawenzi Regional Hospital)</name>
      <address>
        <city>Moshi</city>
        <zip>2236</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>August 22, 2017</results_first_submitted>
  <results_first_submitted_qc>August 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2017</results_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Michael Hoelscher</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>MAMS - Multiple-arm, multiple-stage</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>SQ109</keyword>
  <keyword>High dose rifampicin</keyword>
  <keyword>moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HRZQ</title>
          <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="P2">
          <title>Arm 1 (R35)</title>
          <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="P3">
          <title>HR20ZQ</title>
          <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="P4">
          <title>HR20ZM</title>
          <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="P5">
          <title>HRZE</title>
          <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
Moxifloxacin: Moxifloxacin 400mg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HRZQ</title>
          <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="B2">
          <title>Arm 1 (R35)</title>
          <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="B3">
          <title>HR20ZQ</title>
          <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="B4">
          <title>HR20ZM</title>
          <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="B5">
          <title>HRZE</title>
          <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
Moxifloxacin: Moxifloxacin 400mg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="123"/>
            <count group_id="B6" value="365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="25" upper_limit="40"/>
                    <measurement group_id="B2" value="33" lower_limit="23" upper_limit="40"/>
                    <measurement group_id="B3" value="34" lower_limit="27" upper_limit="41"/>
                    <measurement group_id="B4" value="31" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="B5" value="34" lower_limit="26" upper_limit="41"/>
                    <measurement group_id="B6" value="32.9" lower_limit="23.8" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="94"/>
                    <measurement group_id="B6" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="101"/>
                    <measurement group_id="B6" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Positive Participants</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media</title>
        <description>From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.</description>
        <time_frame>0 - 12 weeks</time_frame>
        <population>Modified intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (R35)</title>
            <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O2">
            <title>HRZQ</title>
            <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O3">
            <title>HR20ZQ</title>
            <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O4">
            <title>HR20ZM</title>
            <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O5">
            <title>HRZE</title>
            <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
Moxifloxacin: Moxifloxacin 400mg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media</title>
          <description>From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.</description>
          <population>Modified intention to treat analysis</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="34" upper_limit="69"/>
                    <measurement group_id="O2" value="63" lower_limit="48" upper_limit="83"/>
                    <measurement group_id="O3" value="66" lower_limit="41" upper_limit="83"/>
                    <measurement group_id="O4" value="55" lower_limit="41" upper_limit="69"/>
                    <measurement group_id="O5" value="62" lower_limit="41" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events</title>
        <description>All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries.</description>
        <time_frame>0 - 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 (R35)</title>
            <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O2">
            <title>HRZQ</title>
            <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O3">
            <title>HR20ZQ</title>
            <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O4">
            <title>HR20ZM</title>
            <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O5">
            <title>HRZE</title>
            <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
Moxifloxacin: Moxifloxacin 400mg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events</title>
          <description>All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Patients with at least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with at least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycobacteriology Identification and Characterization by PCR and MIC</title>
        <description>Cultures grown from the screening period, and the last sputum sample with mycobacteriological growth will be assessed as follows:
Identification of M. tuberculosis complex and RIF resistance by PCR (GeneXpert MTB/RIF®),
First-line drug susceptibility testing of the M. tuberculosis isolates using the MGIT system for sensitivity to rifampicin; isoniazid, pyrazinamide, moxifloxacin or ethambutol.
Minimum inhibitory concentrations (MIC) of SQ109, rifampicin and moxifloxacin.
Typing of the infecting strain(s) by molecular methods.</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Including AUC, Cl, t1/2, Vd, and Protein Binding</title>
        <description>Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:
area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0‐24) (in h*ng/mL)
the observed maximum concentration (Cmax( (in ng/mL)
time to reach Cmax (Tmax)(in hours)
the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),
clearance (Cl) (in mL/minute),
volume of distribution (Vd) (in L),
elimination half‐life (T1/2,) (in hours)
free (protein‐unbound) fraction (for rifampicin only) (in percent).</description>
        <time_frame>0 - 12 weeks</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>HRZQ</title>
            <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O2">
            <title>Arm 1 (R35)</title>
            <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O3">
            <title>HR20ZQ</title>
            <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O4">
            <title>HR20ZM</title>
            <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
          <group group_id="O5">
            <title>HRZE</title>
            <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
Moxifloxacin: Moxifloxacin 400mg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Including AUC, Cl, t1/2, Vd, and Protein Binding</title>
          <description>Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:
area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0‐24) (in h*ng/mL)
the observed maximum concentration (Cmax( (in ng/mL)
time to reach Cmax (Tmax)(in hours)
the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),
clearance (Cl) (in mL/minute),
volume of distribution (Vd) (in L),
elimination half‐life (T1/2,) (in hours)
free (protein‐unbound) fraction (for rifampicin only) (in percent).</description>
          <population>Pharmacokinetic population</population>
          <units>Rifampicin AUC(mg*h/l)</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="4.3" upper_limit="45.3"/>
                    <measurement group_id="O2" value="170" lower_limit="103" upper_limit="266"/>
                    <measurement group_id="O3" value="68.3" lower_limit="38.5" upper_limit="149"/>
                    <measurement group_id="O4" value="57.8" lower_limit="15" upper_limit="121"/>
                    <measurement group_id="O5" value="24.2" lower_limit="11.9" upper_limit="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics Including AUC0‐24/MIC (h*ng/mL) and Cmax/MIC (ng/mL)</title>
        <description>By combining pharmacokinetic parameters and MIC values (see below), the pharmacodynamic indices AUC0‐24/MIC (h*ng/mL) and Cmax/MIC (ng/mL) will be calculated for individual patients for experimental drugs administered. Pharmacokinetic parameters and pharmacodynamic indices will be related to efficacy and safety/tolerability endpoints.</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Negative Culture on Liquid and Solid Media</title>
        <description>Time to a convert to a single negative culture on liquid and solid media</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Negative Sputum Cultures</title>
        <description>Proportion of patients converting to negative sputum culture (2 consecutive weekly cultures) in liquid and solid media</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Time to Positivity</title>
        <description>Rate of change in time to positivity in BD MGIT 960® liquid culture</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Quantitative PCR During Therapy</title>
        <description>GeneXpert MTB/RIF (Xpert) quantitative PCR results (counts per week</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurence of Treatment Failure (Relapse or Emergence of Drug-resistance)</title>
        <description>Frequency of treatment failures (number of patients with relapse and/or development of drug resistance) will be recorded</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Baseline Laboratory Safety Parameters During Treatment and Follow-up</title>
        <description>Frequency tables will be generated for visual acuity tests, 12 lead ECGs, clinical chemistry metrics, haematology, and urinalysis</description>
        <time_frame>0 - 12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HRZQ</title>
          <description>Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="E2">
          <title>Arm 1 (R35)</title>
          <description>Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="E3">
          <title>HR20ZQ</title>
          <description>Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
SQ109: SQ109 300 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="E4">
          <title>HR20ZM</title>
          <description>Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
Rifampicin: Rifampicin 10 to 35 mg/kg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
        <group group_id="E5">
          <title>HRZE</title>
          <description>HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
Rifampicin: Rifampicin 10 to 35 mg/kg
Moxifloxacin: Moxifloxacin 400mg
isoniazid: isoniazid 75 mg
pyrazinamide: pyrazinamide 400 mg
ethambutol: ethambutol 275 mg
pyridoxine: pyridoxine 25 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyper osmolar hyperglycaemia state (diabetic melitus) grade 4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Intrahepatic cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever - hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis of ankles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cerebral fractures due to post motor vehicle accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Parasuicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Parasuicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>left pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Resiratory insufficiency secondary to psnumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Community accuired pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Multi drug resistant TB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="92" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>haemoptysis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Eye irrritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced transiently</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>gastroentertitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Post-tussive vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Salivary gland enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E5" events="16" subjects_affected="15" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Generalized oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>haemarrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>hypercholsterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain in face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>drug induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhinitis seasonal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abcess of eyelid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pericarditis tuberculous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urogenital infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood albumine decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipase decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pregnancy test false positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E5" events="19" subjects_affected="18" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dactylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Excema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>fungal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>herplex zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E5" events="18" subjects_affected="17" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Norbert Heinrich</name_or_title>
      <organization>Tropical Institute of the Ludwig-Maximilians University in Munich, Germany</organization>
      <phone>0049 89 2180 17605</phone>
      <email>heinrich@lrz.uni-muenchen.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

